Hepatitis C virus (HCV) was discovered for the first time in 1989. It causes
chronic liver disease. HCV is a plus-stranded RNA virus and belong to family
Flaviviridae. About 3.3% (20 crore) of global population are infected due to HCV.
Mostly it spread through contaminated syringes. In developed countries prevalence of
HCV is low, e.g. Germany (0·6%), Canada (0·8%), Australia and France (1·1%). Low
but little higher seroprevalence rate have been reported in USA (1·8%), Italy (2·2%) and
Japan (1·5–2·3%). In developing countries including Pakistan its prevalence is high 0.5-
31.9%. Interferon based therapy are used for the treatment of HCVinfection.
%0 Journal Article
%1 muhammadalamzebkhan2013hidden
%A Muhammad, Alam Zeb Khan, Fazal-U-samad
%A Ahmad, Tauseef
%D 2013
%E Ahmad, Tauseef
%J Reviews of Progress
%K (HCV) C Flaviviridae Hepatitis Interferon
%N 31
%T A HIDDEN ENEMY : HCV
%U http://reviewsofprogress.org/UploadedArticle/9.pdf
%V 1
%X Hepatitis C virus (HCV) was discovered for the first time in 1989. It causes
chronic liver disease. HCV is a plus-stranded RNA virus and belong to family
Flaviviridae. About 3.3% (20 crore) of global population are infected due to HCV.
Mostly it spread through contaminated syringes. In developed countries prevalence of
HCV is low, e.g. Germany (0·6%), Canada (0·8%), Australia and France (1·1%). Low
but little higher seroprevalence rate have been reported in USA (1·8%), Italy (2·2%) and
Japan (1·5–2·3%). In developing countries including Pakistan its prevalence is high 0.5-
31.9%. Interferon based therapy are used for the treatment of HCVinfection.
@article{muhammadalamzebkhan2013hidden,
abstract = {Hepatitis C virus (HCV) was discovered for the first time in 1989. It causes
chronic liver disease. HCV is a plus-stranded RNA virus and belong to family
Flaviviridae. About 3.3% (20 crore) of global population are infected due to HCV.
Mostly it spread through contaminated syringes. In developed countries prevalence of
HCV is low, e.g. Germany (0·6%), Canada (0·8%), Australia and France (1·1%). Low
but little higher seroprevalence rate have been reported in USA (1·8%), Italy (2·2%) and
Japan (1·5–2·3%). In developing countries including Pakistan its prevalence is high 0.5-
31.9%. Interferon based therapy are used for the treatment of HCVinfection.
},
added-at = {2014-08-17T12:09:12.000+0200},
author = {{Muhammad, Alam Zeb Khan}, Fazal-U-samad and Ahmad, Tauseef},
biburl = {https://www.bibsonomy.org/bibtex/2d4eea06f04c1ed4df61286961a8ec8c6/sciencejournal},
editor = {Ahmad, Tauseef},
interhash = {c04bcbe6a6770fa0737ac1778560e5ed},
intrahash = {d4eea06f04c1ed4df61286961a8ec8c6},
journal = {Reviews of Progress },
keywords = {(HCV) C Flaviviridae Hepatitis Interferon},
month = {November},
number = 31,
timestamp = {2014-08-17T12:09:12.000+0200},
title = {A HIDDEN ENEMY : HCV
},
url = {http://reviewsofprogress.org/UploadedArticle/9.pdf},
volume = 1,
year = 2013
}